The closing of the transaction is expected in June 2012.

Read the release… Visit Jazz Pharmaceuticals…

We are an established specialty pharmaceutical company with a strong portfolio of 10 specialist hospital products for whom the recent FDA approval of Erwinaze™ signalled our transition into a specialty development as well as commercialization organization.

With a major focus on oncology, oncology supportive care and critical care complemented by a highly developed U.S. commercial infrastructure, broad pan-European coverage and a far-reaching distributor network, we are experiencing significant success in over 80 countries.

In this short video, Dr Tim Corn, Chief Medical Officer at EUSA Pharma, explains the benefits this approval will bring to patients in the US with Acute Lymphoblastic Leukemia and EUSA Pharma’s continued commitment to rare diseases.

Watch the video… Read the News…

There are more than 60 clinical studies evaluating the efficacy of Collatamp for the treatment or prevention of SSIs across a wide variety of surgical procedures including GI/Colorectal, orthopaedic, cardiothoracic, vascular and others.

Our new, comprehensive global website for Caphosol provides a highly informative resource for oral mucositis and Caphosol. Simpler and faster, Caphosol.com provides much richer information, more supporting data and useful handouts with real stories from patients who have experienced oral mucositis.

If you or someone you know are suffering oral mucositis then Caphosol.com may be what you're looking for.